• Search

Search in Site

PharmaDeviceNews | Pharma and Medical Device Industry News PharmaDeviceNews.com
  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
```
Home»Posts tagged with»Demodex blepharitis

Glaukos completes enrollment in GLK-321 trial as Demodex therapy competition grows

By Pallavi Madhiraju on June 28, 2026   Pharma & Biotech  

Glaukos completes enrollment in GLK-321 trial as Demodex therapy competition grows

Discover how Glaukos’ GLK-321 Phase 2 trial could reshape Demodex blepharitis care through a dropless eyelid-applied treatment.

Recent Posts

  • Could Larimar be closer to changing the Friedreich’s ataxia treatment landscape?
  • Nippon Shinyaku backs EXG-7001 as full-length dystrophin mRNA strategy enters Duchenne race
  • Can Anixa’s breast cancer vaccine and lira-cel CAR-T therapy translate early immune signals into clinical benefit?
  • Lupin’s tentative FDA approval for enzalutamide sets up a high-value generic challenge to Xtandi
  • Why LEO Pharma is shifting the chronic hand eczema debate from skin clearance to life impact
  • Glaukos completes enrollment in GLK-321 trial as Demodex therapy competition grows
  • Why Natera’s Prospera could reshape how Eledon measures kidney transplant injury in Phase 3
  • Merck and Gilead secure FDA approval for a new ADC-immunotherapy backbone in advanced TNBC
  • How Johnson & Johnson’s dual-energy THERMOCOOL platform could reshape European atrial fibrillation ablation
  • Gilead expands Trodelvy into first-line metastatic TNBC, but survival questions remain unresolved
  • Ionis Pharmaceuticals moves beyond rare disease as Tryngolza enters the wider triglyceride market
  • Pfizer’s Ibrance wins broader FDA role as metastatic breast cancer treatment becomes more complex
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes